VRTX May 2024 440.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:53PM EDT
| Previous close | 1.3000 |
| Open | 0.6500 |
| Bid | 0.2500 |
| Ask | 1.1000 |
| Strike | 440.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.6500 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 45 |
Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksVertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.
© 2024 Yahoo. All rights reserved.